Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770381791> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2770381791 abstract "Midostaurin is a new orally administered multi-target receptor tyrosine kinase inhibitor for the treatment of Acute Myeloid Leukaemia (AML). It was designated as an orphan medicinal product in 2004. Marketing authorisation was granted for midostaurin on 18th September 2017. The assessment of clinical effectiveness was based on three studies: The RATIFY trial, the IIT-trial and the UK NCRI AML17 trial. RATIFY was a randomised phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3-mutated AML. In total, 717 patients aged 18–60 years were included in the full analysis set of the trial. This was the most important study to this assessment and is the pivotal trial of midostaurin in this indication. Midostaurin in combination with standard induction and consolidation chemotherapy improved overall survival (OS) in patients aged 18–60 years who were fit for chemotherapy. In the RATIFY trial, the risk of death was reduced by 23% during the follow-up for the midostaurin versus placebo groups. The proportion of patients alive in the midostaurin and placebo treatment arms were: 1 year – 76% versus 68%; 5 years – 51% versus 43%. However, because of a plateau effect in the OS curves, the absolute OS gain was difficult to determine reliably. Overall, key secondary outcomes support the conclusions based on the primary outcome (OS). No data on the health-related quality of life or disease-specific quality of life were available. Based on the indirect comparison of midostaurin in combination with standard induction (7+3 regimen) and consolidation chemotherapy versus high-dose (90mg/m2) daunorubicin induction (10+3 regimen) and consolidation chemotherapy, there was no evidence that midostaurin treatment was more beneficial than high-dose daunorubicin used during induction, or vice versa. However, serious limitations apply to this indirect comparison." @default.
- W2770381791 created "2017-12-04" @default.
- W2770381791 creator A5010261671 @default.
- W2770381791 creator A5065562814 @default.
- W2770381791 date "2017-11-01" @default.
- W2770381791 modified "2023-09-27" @default.
- W2770381791 title "Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia. EUnetHTA report" @default.
- W2770381791 hasPublicationYear "2017" @default.
- W2770381791 type Work @default.
- W2770381791 sameAs 2770381791 @default.
- W2770381791 citedByCount "0" @default.
- W2770381791 crossrefType "journal-article" @default.
- W2770381791 hasAuthorship W2770381791A5010261671 @default.
- W2770381791 hasAuthorship W2770381791A5065562814 @default.
- W2770381791 hasConcept C10205521 @default.
- W2770381791 hasConcept C126322002 @default.
- W2770381791 hasConcept C143998085 @default.
- W2770381791 hasConcept C176290653 @default.
- W2770381791 hasConcept C2776481607 @default.
- W2770381791 hasConcept C2776694085 @default.
- W2770381791 hasConcept C2778041864 @default.
- W2770381791 hasConcept C2778623314 @default.
- W2770381791 hasConcept C2778729363 @default.
- W2770381791 hasConcept C2781021840 @default.
- W2770381791 hasConcept C28328180 @default.
- W2770381791 hasConcept C54355233 @default.
- W2770381791 hasConcept C71924100 @default.
- W2770381791 hasConcept C86803240 @default.
- W2770381791 hasConceptScore W2770381791C10205521 @default.
- W2770381791 hasConceptScore W2770381791C126322002 @default.
- W2770381791 hasConceptScore W2770381791C143998085 @default.
- W2770381791 hasConceptScore W2770381791C176290653 @default.
- W2770381791 hasConceptScore W2770381791C2776481607 @default.
- W2770381791 hasConceptScore W2770381791C2776694085 @default.
- W2770381791 hasConceptScore W2770381791C2778041864 @default.
- W2770381791 hasConceptScore W2770381791C2778623314 @default.
- W2770381791 hasConceptScore W2770381791C2778729363 @default.
- W2770381791 hasConceptScore W2770381791C2781021840 @default.
- W2770381791 hasConceptScore W2770381791C28328180 @default.
- W2770381791 hasConceptScore W2770381791C54355233 @default.
- W2770381791 hasConceptScore W2770381791C71924100 @default.
- W2770381791 hasConceptScore W2770381791C86803240 @default.
- W2770381791 hasLocation W27703817911 @default.
- W2770381791 hasOpenAccess W2770381791 @default.
- W2770381791 hasPrimaryLocation W27703817911 @default.
- W2770381791 hasRelatedWork W1969545468 @default.
- W2770381791 hasRelatedWork W2055884944 @default.
- W2770381791 hasRelatedWork W2093654759 @default.
- W2770381791 hasRelatedWork W2148883973 @default.
- W2770381791 hasRelatedWork W2150358226 @default.
- W2770381791 hasRelatedWork W2159746057 @default.
- W2770381791 hasRelatedWork W2285936226 @default.
- W2770381791 hasRelatedWork W2337908372 @default.
- W2770381791 hasRelatedWork W239351467 @default.
- W2770381791 hasRelatedWork W2472387758 @default.
- W2770381791 hasRelatedWork W2564941820 @default.
- W2770381791 hasRelatedWork W2585323947 @default.
- W2770381791 hasRelatedWork W2600516765 @default.
- W2770381791 hasRelatedWork W2606190259 @default.
- W2770381791 hasRelatedWork W2623991167 @default.
- W2770381791 hasRelatedWork W2809011227 @default.
- W2770381791 hasRelatedWork W2823851424 @default.
- W2770381791 hasRelatedWork W2972868802 @default.
- W2770381791 hasRelatedWork W3087144414 @default.
- W2770381791 hasRelatedWork W321613470 @default.
- W2770381791 isParatext "false" @default.
- W2770381791 isRetracted "false" @default.
- W2770381791 magId "2770381791" @default.
- W2770381791 workType "article" @default.